Publication:
Effect of Creatine and Pioglitazone on HK-2 Cell Line Cisplatin Nephrotoxicity

dc.authorscopusid19933498800
dc.authorscopusid55331104000
dc.authorscopusid6701850143
dc.authorscopusid7003365098
dc.contributor.authorGenç, G.
dc.contributor.authorKilinc, V.
dc.contributor.authorBedir, A.
dc.contributor.authorÖzkaya, O.
dc.date.accessioned2020-06-21T13:56:53Z
dc.date.available2020-06-21T13:56:53Z
dc.date.issued2014
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Genç] Gürkan, Department of Pediatric Nephrology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Kilinc] Veli, Department of Biochemistry, Ondokuz Mayis University, Medical School, Samsun, Turkey; [Bedir] Abdulkerim, Department of Biochemistry, Ondokuz Mayis University, Medical School, Samsun, Turkey; [Özkaya] Ozan, Department of Pediatric Nephrology, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractCisplatin is a chemotherapeutic agent, which is used in the treatment of various solid organ cancers, and its main dose limiting side effect of cisplatin is nephrotoxicity. The aim of this study is to investigate the role of pioglitazone and creatine on cisplatin nephrotoxicity in vitro. Real-time cell analyzer system (RTCA) was used for real-time and time-dependent analysis of the cellular response of HK-2 cells following incubation with cisplatin and combination with creatine or pioglitazone hydrochloride. First, half-maximal inhibitory concentrations (IC50) of cisplatin, creatine and pioglitazone were calculated by RTCA system. Afterwards creatine and pioglitazone was administered with serial dilutions under RTCA system. IC50 dose for cisplatin was 7.69M×10-5 at 24th hour and 3.93M×10-6 at 48th hour. IC50 dose for pioglitazone was 1.61M×10-3 at 24th hour and 2.85M×10-4 at 48th hour. Although cells were treated the dose of 40,225mM creatine, IC50 dose could not been reached. Neither pioglitazone nor creatine had additional protective effect in any dose. Consequently, beneficial effect of creatine and pioglitazone on cisplatin-induced cell death could not be found. Further studies and clinical trials are needed to evaluate the effect of different doses of these drugs in cisplatin-induced nephrotoxicity. © 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted.en_US
dc.identifier.doi10.3109/0886022X.2014.926755
dc.identifier.endpage1107en_US
dc.identifier.issn1525-6049
dc.identifier.issue7en_US
dc.identifier.pmid24937012
dc.identifier.scopus2-s2.0-84904658317
dc.identifier.scopusqualityQ2
dc.identifier.startpage1104en_US
dc.identifier.urihttps://doi.org/10.3109/0886022X.2014.926755
dc.identifier.volume36en_US
dc.identifier.wosWOS:000340259600019
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherInforma Healthcare healthcare.enquiries@informa.comen_US
dc.relation.ispartofRenal Failureen_US
dc.relation.journalRenal Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCisplatinen_US
dc.subjectCreatineen_US
dc.subjectDrug Toxicityen_US
dc.subjectPioglitazoneen_US
dc.titleEffect of Creatine and Pioglitazone on HK-2 Cell Line Cisplatin Nephrotoxicityen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files